The 5th U.S. Circuit Court of Appeals heard arguments on Sept. 9 in Louisiana v. FDA, one of three cases threatening nationwide access to mifepristone, the medication used in the majority of abortions in the United States.
While its stakes center on access to mifepristone generally, survivors of intimate partner violence (IPV) may be among the hardest hit by a national restriction on the abortion care drug.
Already living under extreme, sometimes life-threatening, circumstances, survivors have vanishingly few options to care for themselves in the event of a pregnancy. Telehealth treatment and access to mifepristone by mail have been one of the few reprieves offered thus far, and their restriction could pose grave consequences to survivors nationwide.